SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on October 27, 2015. The registrant is a Delaware corporation headquartered in San Diego, California. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The document solely references the attachment of a management presentation.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The filing discloses a presentation (Exhibit 99.1) used by management in meetings and conferences to describe the Company.
Legal Status: The information contained in Item 7.01 and Exhibit 99.1 is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation dated October 2015) for actual business updates, as the 8-K text only references its existence.
- Note that the presentation materials are not legally "filed" and carry different liability standards than the 8-K itself.
- Confirm the company name discrepancy in the request metadata ("Harrow, Inc.") versus the actual registrant ("Imprimis Pharmaceuticals, Inc.").
- Check subsequent filings for financial data, as this 8-K contains no quantitative financial metrics.